

Experience in Clinical Trials in Cardiology & metabolic diseases

Investigator Name: Dr. med. Hans-Eckart Sarnighausen (PI)

Start (Year)	End (Year)	Phase	Indication / Comments	EUDRACT Nr. (if possible) /	Role
2005	2010	IV	Kompetenznetz Vorhofflimmern, BASIS-AF Register		PI
2005	2009	III	Flec SL; atrial fibrillation		PI
2005	2008	III	AntiPAF; atrial fibrillation		PI
2006	2008	III	CIBIS-ELD; systol. Heart failure		PI
2008	2010	III	ROCKET AF; OAC in AF;	2006-004595-13	PI
2007	2008	IIb	KG2110375; SGLT2I in DM2;	2007-001463-29	PI
2009	2015	III	Atmosphere: reduced HF-Trial;	2008-004104-31	PI
2011	2012	IIb	Diabetes; I1R-MC-GLBG;	2010-023231-42	PI
2011	2020	III	EAST AFNET 4; Afib;	2010-021258-20	PI
2011	2013	III	Diabetes; MB 102073;	2010-019797-32	PI
2011	2013	III	Diabetes; MB 102077;	2010-019798-13	PI
2011	2012	III	Diabetes; 14L-MC-ABEC;	2011-000828-15	PI
2011	2012	III	Diabetes; BI 1245.48;	2011-000347-25	PI
2012	2017	III	CANTOS: KHK-Prevention;	2010-022970-14	PI
2015	2019	III	PARAGON: HFpEF-Trial;	2013-001747-31	PI
2015	2017	III	LPS14355 (PCSK-9);	2015-000799-92	PI
2017	2019	III	CANTOS Extension Trial;	2010-022970-14	PI
2018	2019	III	PARALLAX; HFpEF-Trial;	2016-003410-28	PI
2018	2020	III	EMPEROR reduced; HF	2016-002280-34	PI
2018	2021	III	EMPEROR preserved; HF	2016-002278-11	PI
2019	2021	NCT	Lp(a) in patients with CVD;	NCT003887520	PI
2020	2025/26	III	HORIZON; Lp(a)-CVOT	2019-001079-11	PI
2020	2024/25	III	SURPASS-CVOT; Tirzepatide/Dulaglutid	2019-002735-28	PI
2022	2024	NCT	VICTORION-Difference; Inclisiran/OMT	NCT05192941	PI
2023	2023	NCT	MultiSELECT; Lp(a)-Apheresis/OMT	NCT02791802	PI
2023	2027/28	NCT	CABA-HFpEF, AFib-HF	NCT05508256	PI
2024	2028/29	III	LP(a)FRONTIERS CAVS	2022-502135-19-00	PI
2024	2028/29	III	J3L-MC-EZEF, Lp(a)	2023-509190-23-00	PI